Uveal melanoma (UM) is a rare tumor of the eye; its current treatment leads to lower quality-of-life for the patients (sight loss), 50% of whom eventually die from metastases to the liver. The PACT4EYE project aims at the first clinical development of a new technique called photo-activated chemotherapy (PACT) for the treatment of UM. It makes use of a new, patented ruthenium-containing prodrug (Ru-MTI) that must be activated by green or red light to become toxic.